Cynata Therapeutics has reached a pivotal moment in its clinical development journey, marking the completion of the 100-day primary evaluation period for all participants in its Phase 2 trial of CYP-001, a stem cell therapy targeting acute graft-versus-host disease.
Cynata reaches crucial milestone as Phase 2 trial moves toward results
March 30, 2026 Australian Biotech
Latest Video
New Stories
-
Frustrated minister encourages an early negotiation of new agreements
May 14, 2026 - - Latest News -
Long-term study finds continuing Mounjaro helps maintain weight loss
May 14, 2026 - - Latest News -
GBMA welcomes Budget pathway to increasing biosimilar uptake
May 14, 2026 - - Latest News -
There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this
May 14, 2026 - - Latest News -
Disappointment for diabetes advocates in response to Government budget silence
May 13, 2026 - - Latest News -
Updated forecast highlights the real risk of relying on these numbers
May 13, 2026 - - Latest News -
Baxter and MTAA launch Australian Healthcare Manufacturing Leaders Network
May 13, 2026 - - Latest News
